From: Post-marketing surveillance of anti-malarial medicines used in Malawi
Anti-malarial sample | Number of samples | Level of compliance of API content | Remarks | Number and rate of failing samples | ||
---|---|---|---|---|---|---|
API | compliant | noncompliant | ||||
ATS/SP | 4 | ATS | 4 | 0 | All the 4 samples were noncompliant | 4 (100%) |
 | S | 0 | 4 | |||
 | P | 2 | 2 | |||
ATS/SmP | 5 | ATS | 2 | 3 | Compliant APIs did not occur in the same samples therefore all the samples were noncompliant | 5 (100%) |
 |  | Sm | 1 | 4 | ||
 | P | 2 | 3 | |||
ATM/LUM | 41 | ATM | 14 | 27 | Only 2 samples had both APIs being compliant in the same sample. | 39 (95.1%) |
 | LUM | 11 | 30 | |||
DHA/Pp | 14 | DHA | 4 | 10 | Pp API could not be assayed. Based on DHA alone, 4 out of 14 samples were compliant | 10 (71.4%) |
 | Pp | - | - | |||
DHA/SP | 12 | DHA | 0 | 12 | All the samples were noncompliant even though P was 100% compliant | 12 (100%) |
 | S | 1 | 11 | |||
 | P | 12 | 0 | |||
SP | 23 | S | 3 | 20 | Only 2 samples had both APIs being compliant in the same sample | 21 (91.3%) |
 | P | 12 | 11 | |||
QN | 13 | QN | 5 | 8 | 5 out 13 samples were compliant | 8 (61.5%) |
Total | 112 | Â | 73 | 145 | Â | 99 (88.4%) |